Claims for Patent: 9,822,157

« Back to Dashboard

Summary for Patent: 9,822,157

Title:	Hepcidin analogues and uses thereof
Abstract:	The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
Inventor(s):	Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
Assignee:	Protagonist Therapeutics Inc
Application Number:	US14/775,469
Patent Claims:	1. A peptide having the following structural formula I′ (SEQ ID NO: 21) R1′-X′-Y′-R2 (I′) or a pharmaceutically acceptable salt or solvate thereof, wherein R1′ is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C1-C20 alkanoyl or pGlu; R2′ is —NH2 or —OH; X′ is a peptide sequence having the formula Ia′ (SEQ ID NO: 13) X1-X2-X3-X4-X5-X6-X7-X8-X9-X10 (Ia′) wherein X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent; X2 is Thr, Ala, or D-Thr; X3 is His, Lys, D-His or Lys; X4 is Phe, Ala, Dpa or D-Phe; X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro; X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys; X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys; X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile; X9 is Phe or bhPhe; and X10 is Lys, Phe or absent; wherein if Y′ is absent, X7 is Ile; and Y′ is a peptide sequence having the formula IIa′ (SEQ ID NO: 16) Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15 (IIa′) wherein Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent; Y2 is Pro, Ala, Cys, Gly or absent; Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent; Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent; Y5 is Lys, Met, Arg, Ala or absent; Y6 is Gly, Ser, Lys, Ile, Ala, Pro, Val or absent; Y7 is Trp, Lys, Gly, Ala, Ile, Val or absent; Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or absent; Y9 is Cys, Tyr or absent; Y10 is Met, Lys, Arg, Tyr or absent; Y11 is Arg, Met, Cys, Lys or absent; Y12 is Arg, Lys, Ala or absent; Y13 is Arg, Cys, Lys, Val or absent; Y14 is Arg, Lys, Pro, Cys, Thr or absent; and Y15 is Thr, Arg or absent; wherein said peptide of formula I′ is optionally PEGylated on R1′, X′, or Y′, and wherein a side chain of an amino acid of the peptide is optionally conjugated to a lipophilic substituent or polymeric moiety. 2. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein R1′ is hydrogen, isovaleric acid, isobutyric acid or acetyl. 3. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′ is a peptide sequence having formula Ib′ (SEQ ID NO: 14) X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10 (Ib′) wherein X1 is Asp, Ida, pGlu, bhAsp or absent; X4 is Phe or Dpa; X5 is Pro or bhPro; X6 is Ile, Cys or Arg; X7 is Cys, Ile, Leu or Val; X8 is Ile, Lys, Glu, Phe, Gln or Arg; and X10 is Lys or absent. 4. The peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X′ is a peptide sequence having formula Ic′ (SEQ ID NO: 15) X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10 (Ic′) wherein X1 is Asp, Ida, pGlu, bhAsp or absent; X4 is Phe or Dpa; X5 is Pro or bhPro; X8 is Ile, Lys, Glu, Phe, Gln or Arg; and X10 is Lys or absent. 5. A pharmaceutical composition which comprises at least one peptide or pharmaceutically acceptable salt or solvate thereof according to claim 1 and a pharmaceutically acceptable carrier or excipient. 6. The peptide or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X′-Y′ of formula I′ comprises one of the following sequences: (SEQ ID NO: 29) DTHFPICIFGPRSKGWVC; (SEQ ID NO: 38) DTHFPCIIFGPRSKGWVCK; (SEQ ID NO: 128) DTHFPCIIFEPRSKGWVCK; (SEQ ID NO: 164) DTHFPCIIFGPRSKGWACK; (SEQ ID NO: 168) DTHFPCIIFGPRSKGWVCKK; (SEQ ID NO: 57 DTHFPCIIFVCHRPKGCYRRVCR; (SEQ ID NO: 125) DTHFPCIKFGPRSKGWVCK; (SEQ ID NO: 173) DTHFPCIKFKPRSKGWVCK; (SEQ ID NO: 106) DTHFPCIIFGPRSRGWVCK; (SEQ ID NO: 135) DTHFPCIKFGPKSKGWVCK; (SEQ ID NO: 207) DTHFPCIKFEPRSKGCK; (SEQ ID NO: 265) DTHFPCIKFEPKSKGWECK; (SEQ ID NO: 245) DTHFPCIKFEPRSKKCK; (SEQ ID NO: 247) DTHFPCIKFEPRSKGCKK; (SEQ ID NO: 249) DTHFPCIKFKPRSKGCK; (SEQ ID NO: 250) DTHFPCIKFEPKSKGCK; (SEQ ID NO: 314) DTHFPCIKF; (SEQ ID NO: 28) DTHFPCIIF; or (SEQ ID NO: 325) DTKFPCIIF, wherein said peptide is optionally PEGylated on R1′, X′, or Y′, and wherein a side chain of an amino acid of the peptide is optionally conjugated to a lipophilic substituent or polymeric moiety. 7. The peptide or pharmaceutically acceptable salt or solvate thereof of claim 6, comprising one of the following structures: (SEQ ID NO: 29) Isovaleric acid-DTHFPICIFGPRSKGWVC-NH2; (SEQ ID NO: 38) Isovaleric acid-DTHFPCIIFGPRSKGWVCK-NH2; (SEQ ID NO: 128) Isovaleric acid-DTHFPCIIFEPRSKGWVCK-NH2; (SEQ ID NO: 164) Isovaleric acid-DTHFPCIIFGPRSKGWACK-NH2; (SEQ ID NO: 168) Isovaleric acid-DTHFPCIIFGPRSKGWVCKK-NH2; (SEQ ID NO: 57) Isovaleric acid-DTHFPCIIFVCHRPKGCYRRVCR-NH2; (SEQ ID NO: 172) Isovaleric acid-DTHFPCI-(K(PEG8-))FGPRSKGWVCK-NH2; (SEQ ID NO: 173) Isovaleric acid-DTHFPCIKF-(K(PEG8-))PRSKGWVCK-NH2; (SEQ ID NO: 199) Isovaleric acid-DTHFPICIFGPRS-(K(PEG8-))GWVC-NH2; (SEQ ID NO: 200) Isovaleric acid-DTHFPICIFGPRS-(K(PEG4-))GWVC-NH2; (SEQ ID NO: 201) Isovaleric acid-DTHFPCIIFGPRSRGWVC-(K(PEG8))-NH2; (SEQ ID NO: 202) Isovaleric acid-DTHFPCIIFGPRSRGWVC-(K(PEG4))-NH2; (SEQ ID NO: 203) Isovaleric acid-DTHFPCIIFGPRSRGWVC-(K(PEG2))-NH2; (SEQ ID NO: 183) Isovaleric acid-DTHFPCI-(K(Palm-))FGPRSKGWVCK-NH2; (SEQ ID NO: 217) Isovaleric acid-DTHFPCIKF-)K(Palm-))PRSKGWVCK-NH2; (SEQ ID NO: 219) Isovaleric acid-DTHFPCIKFGP-(K(Palm-))SKGWVCK-NH2; (SEQ ID NO: 220) Isovaleric acid-DTHFPCIKFGPRS-(K(Palm-))GWVCK-NH2; (SEQ ID NO: 221) Isovaleric acid-DTHFPCIKFGPRSKGWVC-(K(Palm-))NH2; (SEQ ID NO: 222) Isovaleric acid- DTHFPCI-(K(PEG3-Palm-))FGPRSKGWVCK-NH2; (SEQ ID NO: 223) Isovaleric acid- DTHFPCIKF-(K(PEG3-Palm-))PRSKGWVCK-NH2; (SEQ ID NO: 224) Isovaleric acid- DTHFPCIKFGP-(K(PEG3-Palm-))SKGWVCK-NH2; (SEQ ID NO: 225) Isovaleric acid- DTHFPCIKFGPRS-(K(PEG3-Palm-))GWVCK-NH2; (SEQ ID NO: 226) Isovaleric acid- DTHFPCIKFGPRSKGWVC-(K(PEG3-Palm))-NH2; (SEQ ID NO: 176) Isovaleric acid- DTHFPCIKFGPRSKGWVC-(K(PEG8))-NH2; (SEQ ID NO: 241) Isovaleric acid- DTHFPCI-(K(isoGlu-Palm-))FEPRSKGCK-NH2; (SEQ ID NO: 242) Isovaleric acid- DTHFPCIKF-K(isoGlu-Palm)-PRSKGCK-NH2; (SEQ ID NO: 243) Isovaleric acid- DTHFPCIKFEP-(K(isoGlu-Palm-))SKGCK-NH2; (SEQ ID NO: 265) Isovaleric acid- DTHFPCIKFEP(K(isoGlu-Palm-))SKGWECK-NH2; (SEQ ID NO: 244) Isovaleric acid- DTHFPCIKFEPRS-(K(isoGlu-Palm-))GCK-NH2; (SEQ ID NO: 245) Isovaleric acid- DTHFPCIKFEPRSK-(K(isoGlu-Palm-))CK-NH2; (SEQ ID NO: 246) Isovaleric acid- DTHFPCIKFEPRSKGCK-(K(isoGlu-Palm-))NH2; (SEQ ID NO: 248) Isovaleric acid- DTHFPCI-K(Dapa-Palm)-FEPRSKGCK-NH2; (SEQ ID NO: 249) Isovaleric acid- DTHFPCIK(F-(Dapa-Palm-))PRSKGCK-NH2; (SEQ ID NO: 250) Isovaleric acid- DTHFPCIKFEP-(K(Dapa-Palm-))SKGCK-NH2; (SEQ ID NO: 251) Isovaleric acid- DTHFPCIKFEPRS-(K(Dapa-Palm-))GCK-NH2; (SEQ ID NO: 252) Isovaleric acid- DTHFPCIKFEPRSK-(K(Dapa-Palm-))CK-NH2; (SEQ ID NO: 253) Isovaleric acid- DTHFPCIKFEPRSKGC-(K(Dapa-Palm-))K-NH2; (SEQ ID NO: 254) Isovaleric acid- DTHFPCIKFEPRSKGC(K-(Dapa-Palm))-NH2; (SEQ ID NO: 314) Isolvaleric acid-DTHFPCIKF-NH2; (SEQ ID NO: 314) Hy-DTHFPCIKF-NH2; (SEQ ID NO: 28) Isolvaleric acid-DTHFPCIIF-NH2; (SEQ ID NO: 28) Hy-DTHFPCIIKF-NH2; (SEQ ID NO: 325) Isovaleric acid-DTKFPCIIF-NH2; or (SEQ ID NO: 325) Hy-DTKFPCIIF-NH2. 8. A pharmaceutical composition comprising the peptide or pharmaceutically acceptable salt or solvate thereof of claim 6 and a pharmaceutically acceptable carrier or excipient. 9. A pharmaceutical composition comprising the peptide or pharmaceutically acceptable salt or solvate thereof of claim 7 and a pharmaceutically acceptable carrier or excipient.